公开(公告)号：US20140357844A1

公开(公告)日：2014-12-04

申请号：US14460871

申请日：2014-08-15

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Shu-Hui LIU ,  Wei-Hsien HO ,  Pavel STROP ,  Magdalena Grazyna DORYWALSKA ,  Arvind RAJPAL ,  David Louis SHELTON ,  Thomas-Toan TRAN

IPC: A61K47/48 ,  A61K38/08 ,  C07K16/28

CPC classification number: C07K16/28 ,  A61K38/08 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6869 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3046 ,  C07K16/3069 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.

Abstract translation: 本发明提供特异性结合滋养层细胞表面抗原-2（Trop-2）的抗体。 本发明进一步提供了包含此类抗体的抗体缀合物，编码抗体的核酸，以及获得此类抗体的方法。 本发明还涉及这些抗体和Trop-2抗体缀合物用于治疗与Trop-2表达（例如癌症）如结肠，食管，胃，头颈部，肺， 卵巢癌或胰腺癌。

公开(公告)号：US20210115159A1

公开(公告)日：2021-04-22

申请号：US16951003

申请日：2020-11-18

Applicant: PFIZER INC. ,  RINAT NEUROSCIENCE CORP.

Inventor： Pavel STROP ,  Magdalena Grazyna DORYWALSKA ,  Arvind RAJPAL ,  David SHELTON ,  Shu-Hui LIU ,  Jaume PONS ,  Russell DUSHIN

IPC: C07K17/02 ,  C07K16/30 ,  A61K47/68

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

公开(公告)号：US20150266974A1

公开(公告)日：2015-09-24

申请号：US14677983

申请日：2015-04-03

Applicant: RINAT NEUROSCIENCE CORP. ,  PFIZER INC.

Inventor： Jaume PONS ,  Jeffrey Raymond CHABOT ,  Javier Fernando CHAPARRO RIGGERS ,  Bruce Charles GOMES ,  Hong LIANG ,  Kapil MAYAWALA ,  Jerome Thomas METTETAL, II ,  Arvind RAJPAL ,  David Louis SHELTON

IPC: C07K16/42 ,  C07K16/40 ,  C07K16/28

CPC classification number: C07K16/4291 ,  C07K16/28 ,  C07K16/40 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/21

Abstract: The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the KD or koff ratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent KDs at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound. This can be important when antagonizing a target antigen typically present at high levels (e.g., IgE, DKK1, C5 and SOST). In addition, such antibodies can increase antigen half life when the antigen is a receptor and the receptor has increased clearance when bound to antibody (e.g, GMCSF receptor).

Abstract translation: 本发明涉及与其抗原具有pH依赖性结合的抗体，使得在生理pH（即pH 7.4）下抗原结合的亲和力大于内体pH（即pH6.0或5.5）时的亲和力。 换句话说，pH5.5 / pH7.4或pH6.0 / pH7.4下的KD或koff比大于或等于2,3,4,8,10,16,20,30,40或100 或者更多。 这种pH依赖性抗体优先从内体中的抗原解离。 与抗原为经过抗原介导的清除（例如，PCSK9）的抗原相比，与具有pH 7.4但具有pH依赖性结合的等效KD的抗体相比，可以增加抗体半衰期。 当与抗体（例如IL6）结合时，当抗原经历减少的清除时，具有pH依赖性结合的抗体可降低总抗原半衰期。 具有pH依赖性结合的抗体也可以延长不抗体结合的抗原的降低。 当拮抗通常以高水平存在的靶抗原（例如IgE，DKK1，C5和SOST）时，这可能是重要的。 此外，当抗原是受体时，这种抗体可以增加抗原半衰期，并且当与抗体（例如，GMCSF受体）结合时，该受体具有增加的清除能力。